AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Conference Call which will start at 8:00am ET the same day.

Virtual NanoKnife System Event

Date: Wednesday, January 8, 2025 Time: 9:30am ET Duration: 60 minutes

Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1703585&tp_key=2c4874e6e2

Event Overview

Attendees will gain insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men with prostate tumors.

The event will feature leaders from the Company’s Oncology division discussing the NanoKnife System’s unique mechanism of action and impact on patient care, collaboration with physicians and patient advocacy groups, as well as its market opportunity and commercialization roadmap.

About the NanoKnife System

The NanoKnife System utilizes Irreversible Electroporation technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue.1 Visit nanoknife.com for full product information.

United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue.

Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability.

European Union: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

1 Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. 2010;4 Suppl 1(Suppl 1):S99-S104. doi:10.5009/gnl.2010.4.S1.S99

View source version on businesswire.com: https://www.businesswire.com/news/home/20250106846681/en/

Investors: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO [phone] [e-mail] Media: Saleem Cheeks Vice President, Communications 518-795-1174 [e-mail]